NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/07/2026
Voltar para busca
Dado oficial do USPTO
BEONE MEDICINES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BEONE MEDICINES
ST13
US500000098814620Classe
5, 40, 42, 44
Pedido
98814620
Registro
8337112
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
23
Atualização mais recente
07/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42, 44
Data de depósito
22/10/2024
Data de registro
07/07/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/07/2026
Última transação
07/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
14/11/2025
Primeiro uso no comércio
14/11/2025
Código do desenho
4
Tipo de titular
16
Localização do titular
BASEL, CH
Examinador
QUEEN, ESTHER FELICIA
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BEONE MEDICINES I GMBH
BeiGene Switzerland GMBH
Representantes
Kristen Ruisi Venable LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases
Classe 40
Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases
Classe 42
Research and development of new products for others; technological research in the field of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical research; scientific research in the nature of conducting clinical trials for others for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; electronic data storage; material testing
Classe 44
Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advicepharmaceutical advice
Publicações
Histórico de despachos e eventos da marca no USPTO.
23 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
07/07/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/06/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/06/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
28/05/2026
IUAF
USE AMENDMENT FILED
27/01/2026
EISU
TEAS STATEMENT OF USE RECEIVED
27/01/2026
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/10/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/07/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/06/2025
PUBO
PUBLISHED FOR OPPOSITION
03/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/04/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/04/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
30/03/2025
GNRT
NON-FINAL ACTION E-MAILED
30/03/2025
CNRT
NON-FINAL ACTION WRITTEN
30/03/2025
DOCK
ASSIGNED TO EXAMINER
30/03/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/03/2025
NWAP
NEW APPLICATION ENTERED
22/10/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BEONE MEDICINES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.